All In Biotech

Drug Trial Radar · NCT03615326

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 738 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

738

Actual

Start

Oct 5, 2018

Primary completion

Mar 20, 2024

Study completion Nov 12, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).

Conditions

  • Gastric Neoplasms
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • PembrolizumabBiological

    200 mg on Day 1 of each 3-week cycle as an IV infusion.

  • PlaceboBiological

    Solution for IV infusion on Day 1 of each 3-week cycle.

  • CisplatinDrug

    80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.

  • 5-FUDrug

    800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.

  • OxaliplatinDrug

    130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.

  • CapecitabineDrug

    1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.

  • S-1Drug

    Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.

  • TrastuzumabBiological

    8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICRTime frame: Up to approximately 46 months
  2. Overall Survival (OS)Time frame: Up to approximately 63 months

Locations

192 sites in 20 countries. Site status is shown where the registry gives one.

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0045)

    Los Angeles, California

  • Pacific Cancer Care ( Site 0063)

    Monterey, California

  • UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0050)

    Orange, California

  • University of Miami Sylvester Comprehensive Cancer Center - Plantation ( Site 0026)

    Miami, Florida

  • Southeastern Regional Medical Center, Inc. ( Site 0058)

    Newnan, Georgia

  • Midwestern Regional Medical Center, Inc. ( Site 0059)

    Zion, Illinois

  • Beth Israel Deaconess Medical Center ( Site 0070)

    Boston, Massachusetts

  • Dana-Farber Cancer Institute [Boston, MA] ( Site 0010)

    Boston, Massachusetts

  • Minnesota Oncology Hematology, PA ( Site 8001)

    Minneapolis, Minnesota

  • Washington University School of Medicine ( Site 0040)

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0071)

    Middletown, New Jersey

  • Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0065)

    Harrison, New York

  • Memorial Sloan-Kettering Cancer Center ( Site 0017)

    New York, New York

  • University of Rochester ( Site 0041)

    Rochester, New York

  • Levine Cancer Institute ( Site 0015)

    Charlotte, North Carolina

  • Duke Cancer Institute ( Site 0042)

    Durham, North Carolina

  • CTCA Southwestern ( Site 0060)

    Tulsa, Oklahoma

  • Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025)

    Philadelphia, Pennsylvania

  • Allegheny General Hospital ( Site 0053)

    Pittsburgh, Pennsylvania

  • Sanford Hematology Oncology-Sioux Falls SD ( Site 0004)

    Sioux Falls, South Dakota

  • University of Texas MD Anderson Cancer Center ( Site 0001)

    Houston, Texas

  • Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8000)

    Roanoke, Virginia

  • Seattle Cancer Care Alliance ( Site 0038)

    Seattle, Washington

  • Liverpool Hospital ( Site 2206)

    Liverpool, New South Wales, Australia

  • Westmead Hospital ( Site 2200)

    Westmead, New South Wales, Australia

  • Southern Medical Day Care Centre ( Site 2207)

    Wollongong, New South Wales, Australia

  • Monash Health ( Site 2202)

    Clayton, Victoria, Australia

  • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0201)

    Rio de Janeiro, Brazil

  • IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0204)

    São Paulo, Brazil

  • Instituto do Cancer do Ceara ( Site 0208)

    Fortaleza, Ceará, Brazil

  • Hospital Sao Rafael ( Site 0209)

    Salvador, Estado de Bahia, Brazil

  • CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0205)

    Curitiba, Paraná, Brazil

  • Hospital de Caridade de Ijui ( Site 0202)

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao ( Site 0203)

    Porto Alegre, Rio Grande do Sul, Brazil

  • CEPON - Centro de Pesquisas Oncologicas ( Site 0200)

    Florianópolis, Santa Catarina, Brazil

  • Centro Investigación del Cáncer James Lind ( Site 0300)

    Temuco, Araucania, Chile

  • Clinica Universidad Catolica del Maule ( Site 0305)

    Talca, Maule Region, Chile

  • Fundacion Arturo Lopez Perez FALP ( Site 0302)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile ( Site 0301)

    Santiago, Region M. de Santiago, Chile

  • Instituto Nacional del Cancer ( Site 0303)

    Santiago, Region M. de Santiago, Chile

Showing 40 of 192 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.